Although immune checkpoint blockade (ICB) therapy targeting PD-1/PD-L1 has shown remarkable efficacy in a subset of microsatellite instability-high (MSI-H) CRC patients, the majority of microsatellite-stable (MSS) tumors exhibit limited or no response (6, 7). This evidence concerns the gene CD274 and colorectal carcinoma.